Jane Street’s Arcutis Biotherapeutics ARQT Stock Holding History

Jane Street’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.09M	Sell	117,800 -14,000	-11%	-$326K	﹤0.01%	4462
2026 Q1	$3.11M	Buy	131,800 +34,000	+35%	+$868K	﹤0.01%	4283
2025 Q4	$2.84M	Buy	97,800 +50,500	+107%	+$1.29M	﹤0.01%	4141
2025 Q3	$892K	Sell	47,300 -5,500	-10%	-$86.7K	﹤0.01%	6570
2025 Q2	$740K	Buy	52,800 +26,700	+102%	+$374K	﹤0.01%	6188
2025 Q1	$408K	Sell	26,100 -21,500	-45%	-$303K	﹤0.01%	7242
2024 Q4	$663K	Sell	47,600 -15,400	-24%	-$169K	﹤0.01%	6165
2024 Q3	$586K	Buy	+63,000	New	+$622K	﹤0.01%	6916
2023 Q3	–	Sell	-123,600	Closed	-$1.18M	–	8584
2023 Q2	$1.18M	Buy	+123,600	New	+$1.37M	﹤0.01%	4959
2022 Q3	–	Sell	-85,200	Closed	-$1.82M	–	9652
2022 Q2	$1.82M	Buy	+85,200	New	+$1.75M	﹤0.01%	4349

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jane Street's ARQT Position: Q2 2026 in Review

Jane Street reduced its Arcutis Biotherapeutics (ARQT) stake by 83% in Q2 2026, selling an estimated $5.45M and leaving 49,586 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #5986.

Jane Street first reported a position in ARQT in Q3 2020 and has held it in 17 quarters since. The position peaked at $6.8M in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Jane Street held 49,586 shares of Arcutis Biotherapeutics worth $1.3M as of Q2 2026.
Jane Street sold 234,037 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.45M.
Arcutis Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5986 holding.
Jane Street first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 17 quarters since.
Jane Street's Arcutis Biotherapeutics position peaked at $6.8M in Q3 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.